Continuous intra-arterial chemotherapy for downstaging locally advanced oral commissure carcinoma

被引:7
作者
Wu, Chih-Fung [1 ]
Chang, Kao-Ping [1 ]
Huang, Chih-Jen [2 ]
Chen, Chun-Ming [3 ]
Chen, Ching-Yi [3 ]
Lin, Chen-Lung Steve [1 ]
机构
[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Dept Surg, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Kaohsiung 807, Taiwan
[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Dent Med, Dept Oral & Maxillofacial Surg, Kaohsiung 807, Taiwan
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2014年 / 36卷 / 07期
关键词
squamous cell carcinoma; oral commissure; intra-arterial infusion; chemotherapy; methotrexate; QUALITY-OF-LIFE; ADVANCED HEAD; NECK-CANCER; INDUCTION CHEMOTHERAPY; OROPHARYNGEAL CANCER; PRIMARY SURGERY; LIP CANCER; CISPLATIN; INFUSION; IRRADIATION;
D O I
10.1002/hed.23408
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. The purpose of this study was to assess the usefulness, safety, and efficacy of intra-arterial (IA) infusion chemotherapy for patients with locally advanced oral commissure cancer. Methods. Twenty-one patients with stages III and IV squamous cell carcinoma involving the mouth angle were recruited. Methotrexate (MTX; 50 mg/day) was continuously infused into the external carotid artery for a mean period of 8 days, followed by weekly IA bolus of 25 mg MTX for a mean period of 10 weeks. Results. Thirteen patients (62%) achieved a complete response (CR) and 7 patients (33%) had a partial response (PR). At a median follow-up of 69 months, the estimated 1-year, 3-year, and 5-year survival rates of the patients with CR versus PR were 100% versus 57%, 92% versus 43%, and 80% versus 43%, respectively. Conclusion. Our data demonstrate that continuous IA chemotherapy could achieve a competitive acceptable survival rate and improved locoregional control of advanced oral commissure cancer. (C) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1027 / 1033
页数:7
相关论文
共 35 条
  • [1] [Anonymous], 1979, HDB REP RES CANC TRE
  • [2] [Anonymous], 1991, NEW ENGL J MED
  • [3] Immediate impact of primary surgery on health-related quality of life of hospitalized patients with oral and oropharyngeal cancer
    Biazevic, Maria G. H.
    Ferreira Antunes, Jose Leopoldo
    Togni, Janina
    de Andrade, Fabiana P.
    de Carvalho, Marcos B.
    Wuensch-Filho, Victor
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2008, 66 (07) : 1343 - 1350
  • [4] BLEYER WA, 1989, CANCER-AM CANCER SOC, V63, P995
  • [5] Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998
    Canto, MT
    Devesa, SS
    [J]. ORAL ONCOLOGY, 2002, 38 (06): : 610 - 617
  • [6] CHEUNG DK, 1988, CANCER-AM CANCER SOC, V61, P903, DOI 10.1002/1097-0142(19880301)61:5<903::AID-CNCR2820610508>3.0.CO
  • [7] 2-O
  • [8] Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma
    Denis, F
    Garaud, P
    Bardet, E
    Alfonsi, M
    Sire, C
    Germain, T
    Bergerot, P
    Rhein, B
    Tortochaux, J
    Calais, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 69 - 76
  • [9] PALLIATIVE, INTRAARTERIAL CHEMOTHERAPY FOR ADVANCED HEAD AND NECK-CANCER USING AN IMPLANTABLE PORT SYSTEM
    ECKARDT, A
    KELBER, A
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 1994, 52 (12) : 1243 - 1246
  • [10] Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials
    ElSayed, S
    Nelson, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 838 - 847